Last reviewed · How we verify
NCT06639932
We-INtervention Among Chinese HIV-serodiscordant Male Couples
NA trial testing We-INtervention in HIV in 320 participants. Currently enrolling.
30 April 2027
Quick facts
| Lead sponsor | City University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 320 |
| Start date | 1 September 2025 |
| Primary completion | 30 April 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 4 locations across China |
Drugs / interventions tested
- We-INtervention
- Usual Care Group — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
Sponsor
City University of Hong Kong
Who can join
18 and older, male only, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HIV-serodiscordant male couples, in which one male partner is HIV-seropositive and the other is HIV-seronegative, experience multiple risks in HIV care and prevention. As stigma often hinders such couples' access to support and services, leveraging their relational resources is crucial for optimizing their outcomes. The proposed study will assess the efficacy of the three-session We-INtervention focusing on their relationship dynamics to enhance Chinese HIV-serodiscordant male couples' health and well-being. A total of 160 Chinese HIV-serodiscordant male couples (320 individuals: 160 HIV-seropositive and 160 HIV-seronegative) will be randomized at a 1:1 ratio to either the intervention or control arm. In the intervention arm, the We-INtervention will be delivered to both partners of each couple separately. In the control arm, each couple will receive health information pamphlets.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06639932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other City University of Hong Kong trials
Trials by the same sponsor.
- NCT07374653 — Online Self-healing Program · NA · not yet recruiting
- NCT07371962 — Sound Bite-- a Therapeutic Song-writing Program · NA · recruiting
- NCT07392632 — MindfulCityU-- A Mindfulness Mobile Application for Promoting University Students' Mental Health · NA · not yet recruiting
- NCT07372066 — Cognitive Stimulation Therapy Group for Residential Home Residents With Dementia and Mild Cognitive Impairment · NA · recruiting
- NCT07371988 — Efficacy of Narrative Therapy for Older People With Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06639932 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City University of Hong Kong
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing